View in EDS PDF Full Text

Optimised glucocorticoid therapy: the sharpening of an old spear.

Saved in:
Bibliographic Details
Title: Optimised glucocorticoid therapy: the sharpening of an old spear.
Authors: Buttgereit, Frank, Burmester, Gerd-Rüdiger, Lipworth, Brian J.
Source: Lancet. 2/26/2005, Vol. 365 Issue 9461, p801-803. 3p. 2 Diagrams.
Subjects: Glucocorticoids, Adrenocortical hormones, Anti-inflammatory agents, Drug side effects, Pediatric therapy
Abstract: Context Glucocorticoids are frequently and successfully used drugs that mediate important immunosuppressive and anti-inflammatory effects. These drugs are also relatively inexpensive, but it is their broad range of adverse reactions that continuously stimulate efforts to optimise glucocorticoid treatment. Starting point Last year, Mary Leonard and colleagues studied 60 children and adolescents with nephrotic syndrome intermittently treated with high-dose glucocorticoids (N Engl J Med 2004; 351: 868-75). The patients received an average of 23 g glucocorticoids and were significantly shorter, had a significantly greater body-mass index, and the prevalence of obesity was significantly higher than in controls. The expected deficits in the bone-mineral content of the spine or whole body were not seen, although this finding could be attributed to the highly increased body-mass index of many of the patients. Where next Glucocorticoids are urgently needed to treat a wide range of diseases in children and adults. Therefore strategies such as preferred local application or fine-tuned dose regimens have been developed over the past five decades to improve the benefit-risk ratio. However, these efforts with conventional glucocorticoid drugs seem to have almost reached their limits. A further improvement needs qualitatively new drugs, which are currently in the development pipeline, with the most promising being the nitrosoglucocorticoids (nitrosteroids) and selective glucocorticoid-receptor agonists. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 16224766
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Optimised glucocorticoid therapy: the sharpening of an old spear.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Buttgereit%2C+Frank%22">Buttgereit, Frank</searchLink><br /><searchLink fieldCode="AR" term="%22Burmester%2C+Gerd-Rüdiger%22">Burmester, Gerd-Rüdiger</searchLink><br /><searchLink fieldCode="AR" term="%22Lipworth%2C+Brian+J%2E%22">Lipworth, Brian J.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 2/26/2005, Vol. 365 Issue 9461, p801-803. 3p. 2 Diagrams.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Glucocorticoids%22">Glucocorticoids</searchLink><br /><searchLink fieldCode="DE" term="%22Adrenocortical+hormones%22">Adrenocortical hormones</searchLink><br /><searchLink fieldCode="DE" term="%22Anti-inflammatory+agents%22">Anti-inflammatory agents</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+side+effects%22">Drug side effects</searchLink><br /><searchLink fieldCode="DE" term="%22Pediatric+therapy%22">Pediatric therapy</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Context Glucocorticoids are frequently and successfully used drugs that mediate important immunosuppressive and anti-inflammatory effects. These drugs are also relatively inexpensive, but it is their broad range of adverse reactions that continuously stimulate efforts to optimise glucocorticoid treatment. Starting point Last year, Mary Leonard and colleagues studied 60 children and adolescents with nephrotic syndrome intermittently treated with high-dose glucocorticoids (N Engl J Med 2004; 351: 868-75). The patients received an average of 23 g glucocorticoids and were significantly shorter, had a significantly greater body-mass index, and the prevalence of obesity was significantly higher than in controls. The expected deficits in the bone-mineral content of the spine or whole body were not seen, although this finding could be attributed to the highly increased body-mass index of many of the patients. Where next Glucocorticoids are urgently needed to treat a wide range of diseases in children and adults. Therefore strategies such as preferred local application or fine-tuned dose regimens have been developed over the past five decades to improve the benefit-risk ratio. However, these efforts with conventional glucocorticoid drugs seem to have almost reached their limits. A further improvement needs qualitatively new drugs, which are currently in the development pipeline, with the most promising being the nitrosoglucocorticoids (nitrosteroids) and selective glucocorticoid-receptor agonists. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=16224766
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(05)17989-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 3
        StartPage: 801
    Subjects:
      – SubjectFull: Glucocorticoids
        Type: general
      – SubjectFull: Adrenocortical hormones
        Type: general
      – SubjectFull: Anti-inflammatory agents
        Type: general
      – SubjectFull: Drug side effects
        Type: general
      – SubjectFull: Pediatric therapy
        Type: general
    Titles:
      – TitleFull: Optimised glucocorticoid therapy: the sharpening of an old spear.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Buttgereit, Frank
      – PersonEntity:
          Name:
            NameFull: Burmester, Gerd-Rüdiger
      – PersonEntity:
          Name:
            NameFull: Lipworth, Brian J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 02
              Text: 2/26/2005
              Type: published
              Y: 2005
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 365
            – Type: issue
              Value: 9461
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1